Skip to content

Earnings yield at other companies

Merck & Co. logo
Merck & Co.MRK
3%-4.7pp
Delcath Systems logo
Delcath SystemsDCTH
0.3%+0.2pp
Iovance Biotherapeutics, Inc. logo
Iovance Biotherapeutics, Inc.IOVA
-24.5%-5.5pp
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
-25.7%-6.8pp
Immunome logo
ImmunomeIMNM
-9.1%-3.9pp
Arcus Biosciences logo
Arcus BiosciencesRCUS
-13.6%-5.7pp

Other financials

Income statement

See full
Revenue$1.7M
Gross profit$1.3M
Operating income-$28.6M-283%
Net income-$26.6M-244%
EPS (diluted)-$0.27-145%

Balance sheet

See full
Cash & equivalents$2.6M+2,350,466%
Total equity$35.3M-1.0%
Total assets$100.7M+10.1%

Cash flow

See full
Operating cash flow-$3.8M-179%

Valuation

See full
Market cap$60.45M-74.7%

Returns & leverage

See full
Return on equity-119.9%+46.7pp
Current ratio0.5×+0.1×

Where this comes from

Calculated from Citius Oncology, Inc.’s reported figures.

Based on trailing twelve months.

The official record: Citius Oncology, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about Citius Oncology, Inc.'s earnings yield.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Citius Oncology, Inc.'s earnings yield?
Citius Oncology, Inc. (CTOR) reported earnings yield of -77.7% in Q1 2026.
How has Citius Oncology, Inc.'s earnings yield changed year-over-year?
Citius Oncology, Inc.'s earnings yield decreased by 99.0% year-over-year, from -39% to -77.7%.
What does earnings yield mean?
Trailing-twelve-month net income divided by market capitalization at the quarter end — the inverse of the P/E ratio, expressed as a percentage.